Over the last decade, two important strategies have been developed for the systemic treatment of melanoma: PD-1 based immune checkpoint inhibition (ICI) and targeted therapy (TT) with BRAF and MEK in-hibitors. The gene discussed is BRAF; the disease is melanoma.